Berinert®() | Sajazir®(Icatibant) |
|---|---|
Prescription Only | Prescription Only |
| Dosage & Administration | Dosage & Administration comparison data |
Administration | |
Intravenous. Learn more. | Subcutaneous. Learn more. |
Dosing | |
Administer 20 International Units per kg body weight.. Learn more. | 30 mg injected subcutaneously in the abdominal area. If response is inadequate or symptoms recur, additional injections of 30 mg may be administered at intervals of at least 6 hours. . Learn more. |
Latin Shorthand | |
Administer 20 IU/kg BW.. Learn more. | 30 mg SC (subcutaneous) in abdomen. If inadequate response or recurring symptoms, administer additional 30 mg injections at ≥6-hour intervals.. Learn more. |
| Financial Assistance | Financial Assistance comparison data |
Out-Of-Pocket Costs With Copay Card | |
Annual Cap | |
Assistance Expiration | |
Generics | |
No lower-cost generic available | No lower-cost generic available |
| Physician Advisory | Physician Advisory comparison data |
Adverse Reactions | |
The most serious adverse reaction reported in subjects who received BERINERT was
an increase in the severity of pain associated with HAE.
•The most common adverse reaction reported in greater than 4% of the subjects
and greater than placebo among subjects who received BERINERT in the placebo-controlled clinical trial was dysgeusia.. Learn more. | The most commonly reported adverse reactions were injection site reactions,
which occurred in almost all patients (97%) in clinical trials. Other common
adverse reactions occurring in greater than 1% of patients included pyrexia,
transaminase increase, dizziness, and rash. . Learn more. |
Mechanism of Actions (MoA) | |
Drugs used in Hereditary Angioedema. Learn more. | Drugs used in Hereditary Angioedema. Learn more. |
Special Populations | |